Effect and Safety of Marealis RPC (Refined Peptide Concentrate) in Mild or Moderate Hypertensive Subjects
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 144 participants.
Also called NCT01974570
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose prevention
- Phase
- Phase 2
- Enrolled
- 144 participants
- Sponsor
- KGK Science Inc.
- Registry
-
NCT01974570
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Canada, Czechia, Germany
- Registry status
- Completed
Technical summary
Registry record NCT01974570. Randomized; triple masking; primary purpose prevention. Start 2013-11 (registry gives no type); primary completion 2015-11 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect and Safety of Marealis RPC (Refined Peptide Concentrate) in Mild or Moderate Hypertensive Subjects
- Condition
- Prehypertension
- Intervention (Dietary supplement)
- Marealis refined peptide concentrate
- Intervention (Dietary supplement)
- Placebo
- Lead sponsor
- KGK Science Inc.
- Collaborator
- Marealis AS
Record details
- Record id
cardio:ct-nct01974570- Content hash
9fe0c74286336c152230b7f41f32538e8b6cc8e91a3a8b7847f768184432db08